Skip to end of metadata
Go to start of metadata
You are viewing an old version of this page. View the current version.
Compare with Current
View Page History
« Previous
Version 8
Next »
Attendees
| Attended | Name | Affiliation |
---|
1 | | Cary Paul | Pivotal Insight, LLC. |
2 | x | David Crooke | Pivotal Insight, LLC. |
3 | | Amy Stowers | Maximus |
4 | x | Ken Rubin | VA/Utah |
5 | x | Linda Chan | Pivotal Insight, LLC. |
6 | x | Dhruv Sharma | ACEP |
7 | x | John Svirbely | Trisotech |
8 | x | Shane McNamee | Perspecta |
9 | | Tracie Berardi | OMG |
10 | x | Pawan Goyal | ACEP |
11 | x | Mike Cesino | Visible Systems Corporation |
12 | x | Mike Meier | |
Agenda and Minutes
Meeting Notes |
---|
Business Use Case Analysis Statement of Value What is the benefits What are the key value statements for different action and communications Target Audience: Arriving toward and organization that wants to do authoring of clinical pathways Differentiate between those that want to do authoring verse those that are trying to consume authored artifacts
Out of Scope of Authoring Work group Why an institution would want to adopt or institute shareable pathways Bill: Are there studies about how pathways are instituted and used, and the implications of that. (ref: Look at oncology Pathways)
Examples: Clinical Pathways: Reducing Costs and Improving Quality Across a Network Impact of Electronically Accessible Pathways on Clinical Trial Enrollment at a Large Multisite Cancer Center Work What Success looks like? (6-12 mos) Why would someone want to be involved What is the path-How do I start, and what does the path look like? Best practices-how do I do this well ? What has been learned? What guidance should I follow? Why should I want to be an author involved in BPM+? “How does one take a 100+page PDF guideline and make it into a machine readable model that could be ingested into a system.” Taking the story, approach, tips, tricks, etc. so that other can do this. Either de novo or adapting existing content. This is authoring. New clinical societies Healthcare delivery orgs Etc.
Why would an organization choose this ? If we make the decision, how do we make it so? What does “doing it well” looks like: (e.g. Maturity Model, etc.)
Sample: The Product Vision Board |
Work Products to do this |
Work Products to do this What is the artifact: Value Proposition for Authoring Organizations What is the purpose Explain why formal authoring is valuable Helping advance usability of EHRs: role in improving efficacy of EHR Marrying CPGs into clinical practice congruent to clinical workflow; Making these more consumable and implementable
Who is its audience: As a Technologies: Clinical embeds supporting technology companies As a Functional: Full spectrum clinical community, those building guidelines or maintaining them; Business: secondary reference Adopting organization: rationalize the art of the possible; value of direct consumption of guidelines. Specialty Societies: Authoritative creators or stewards of content. Payers:
Contents: Mission Specific Purpose “Customers” Problem being solved Unique value proposition Case Studies/Exemplars
|
Action items: |
Next Mtgs:
Authoring Clinical Steering Committee on Thursday, July 9, 12:00PM – 1:00pm EST
Workgroup on Monday, July 20 2:30pm – 4pm EST
Authoring Clinical Steering Committee on Thursday, Aug 23, 12:00PM – 1:00pm EST
Workgroup on Monday, August 3 2:30pm – 4pm EST